The IPC has issued a drug safety alert alerting healthcare providers and patients to watch adverse responses of Meftal, a painkiller used for menstrual cramps and rheumatoid arthritis.
The Indian Pharmacopoeia Commission (IPC) has advised doctors and patients to observe Meftal side effects, used for menstrual cramps and rheumatoid arthritis. Rheumatoid arthritis, osteoarthritis, dysmenorrhoea, mild to moderate pain, inflammation, fever, and tooth discomfort are treated with mefenamic acid.
According to the commission’s caution, a preliminary review of adverse medication responses from the Pharmacovigilance Programme of India (PvPI) database showed DRESS syndrome.
“Healthcare professionals, patients/consumers are advised to closely monitor the possibility of the above adverse drug reaction (ADR) associated with the suspected drug,” the November 30 alert stated.
The advisory urged reporting such reactions to the commission’s national coordination centre of the PvPI by filling out a form on www.ipc.gov.in or using the android mobile app ADR PvPI and the PvPI Helpline 1800-180-3024.
IPC, an autonomous ministry of health agency, sets standards for all Indian pharmaceuticals made, sold, and consumed.
Conclusion
The Indian Pharmacopoeia Commission (IPC) has issued a drug safety advisory recommending healthcare providers and patients to watch Meftal side effects, used to treat menstrual cramps and rheumatoid arthritis. The alert notes that a preliminary study of adverse medication reactions from the Pharmacovigilance Programme of India (PvPI) database found DRESS syndrome. Report such reactions to the PvPI national coordinating center. In India, the IPC regulates all pharmaceuticals made, sold, and consumed.
